Niels Harlaar

Niels Harlaar

Auto-generated profile, based on publicly available information

Niels Harlaar

Laboratory of Experimental Cardiology, Department of Cardiology, Leiden University Medical Center , Leiden , the Netherlands

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2022 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
NHNiels Harlaar
Niels Harlaar
SDSven O. Dekker
Sven O. Dekker
JZJuan Zhang
Juan Zhang
RSRebecca R. Snabel
Rebecca R. Snabel
MVMarieke W. Veldkamp
Marieke W. Veldkamp
AVAntoine de Vries
Antoine de Vries

8 June 2020 in eLife
Verified
Journal Article
Open access
RMRupamanjari Majumder
Rupamanjari Majumder
TCTim De Coster
Tim De Coster
NKNina Kudryashova
Nina Kudryashova
Arie O. VerkerkArie O. Verkerk
Arie O. Verkerk
IKIvan V Kazbanov
Ivan V Kazbanov
DPDaniël A Pijnappels
Daniël A Pijnappels
Homeostatic regulation protects organisms against hazardous physiological changes. However, such regulation is limited in certain organs and associated biological processes. For example, the heart fails to self-restore its normal electrical activity once disturbed, as with sustained arrhythmias. Here we present proof-of-concept of a biological self-restoring system that allows automatic detection and correction of such abnormal excitation rhythms. For the heart, its realization involves the integration of ion channels with newly designed gating properties into cardiomyocytes. This allows cardiac tissue to i) discriminate between normal rhythm and arrhythmia based on frequency-dependent gating and ii) generate an ionic current for termination of the detected arrhythmia. We show in silico, that for both human atrial and ventricular arrhythmias, activation of these channels leads to rapid and repeated restoration of normal excitation rhythm. Experimental validation is provided by injecting the designed channel current for arrhythmia termination in human atrial myocytes using dynamic clamp.

1 August 2020 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
NHNiels Harlaar
Niels Harlaar
NVNiels J. Verberkmoes
Niels J. Verberkmoes
PVPepijn H. van der Voort
Pepijn H. van der Voort
STSerge A. Trines
Serge A. Trines
SVStefan E. Verstraeten
Stefan E. Verstraeten
TBThomas J. van Brakel
Thomas J. van Brakel

27 December 2021 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
PDF file
NHNiels Harlaar
Niels Harlaar
MOMaurice A Oudeman
Maurice A Oudeman
STSerge A Trines
Serge A Trines
GRGijsbert S de Ruiter
Gijsbert S de Ruiter
BMBart J Mertens
Bart J Mertens
TBThomas J van Brakel
Thomas J van Brakel
Catheter ablation of long-standing persistent atrial fibrillation (LSPAF) remains challenging, with suboptimal success rates obtained following multiple procedures. Thoracoscopic ablation has shown effective at creating transmural lesions around the pulmonary veins and box; however, long-term rhythm follow-up data are lacking. This study aims, for the first time, to assess the long-term outcomes of thoracoscopic pulmonary vein and box ablation in LSPAF. Rhythm follow-up consisted of continuous rhythm monitoring using implanted loop recorders or 24-h Holter recordings. Rhythm status and touch-up interventions were assessed up to 5 years. Seventy-seven patients with symptomatic LSPAF underwent thoracoscopic ablation in 2 centres. Freedom from atrial arrhythmias at 5 years was 50% following a single thoracoscopic procedure and 68% allowing endocardial touch-up procedures (performed in 21% of patients). The mean atrial fibrillation burden in patients with continuous monitoring was reduced from 100% preoperatively to 0.1% at the end of the blanking period and 8.0% during the second year. Antiarrhythmic drug use decreased from 49.4% preoperative to 12.1% and 14.3% at 2 and 5 years, respectively (P < 0.001). Continuous rhythm monitoring resulted in higher recurrence detection rates compared to 24-h Holter monitoring at 2-year follow-up (hazard ratio: 6.5, P = 0.003), with comparable recurrence rates at 5-year follow-up. Thoracoscopic pulmonary vein and box isolation are effective in long-term restoration of sinus rhythm in LSPAF, especially when complemented by endocardial touch-up procedures, as demonstrated by the 68% freedom rate at 5 years. Continuous rhythm monitoring revealed earlier, but not more numerous documentation of recurrences at 5-year follow-up.

20 October 2010 in Journal of Visualized Experiments
Verified
Journal Article
Open access
PDF file
LCLucia M.A. Crane
Lucia M.A. Crane
GTGeorge Themelis
George Themelis
KBK. Tim Buddingh
K. Tim Buddingh
NHNiels J. Harlaar
Niels J. Harlaar
Rick G. PleijhuisRick G. Pleijhuis
Rick G. Pleijhuis
GDGooitzen M. Van Dam
Gooitzen M. Van Dam
The prognosis in virtually all solid tumors depends on the presence or absence of lymph node metastases.1-3 Surgical treatment most often combines radical excision of the tumor with a full lymphadenectomy in the drainage area of the tumor. However, removal of lymph nodes is associated with increased morbidity due to infection, wound breakdown and lymphedema.4,5 As an alternative, the sentinel lymph node procedure (SLN) was developed several decades ago to detect the first draining lymph node from the tumor.6 In case of lymphogenic dissemination, the SLN is the first lymph node that is affected (Figure 1). Hence, if the SLN does not contain metastases, downstream lymph nodes will also be free from tumor metastases and need not to be removed. The SLN procedure is part of the treatment for many tumor types, like breast cancer and melanoma, but also for cancer of the vulva and cervix.7 The current standard methodology for SLN-detection is by peritumoral injection of radiocolloid one day prior to surgery, and a colored dye intraoperatively. Disadvantages of the procedure in cervical and vulvar cancer are multiple injections in the genital area, leading to increased psychological distress for the patient, and the use of radioactive colloid. Multispectral fluorescence imaging is an emerging imaging modality that can be applied intraoperatively without the need for injection of radiocolloid. For intraoperative fluorescence imaging, two components are needed: a fluorescent agent and a quantitative optical system for intraoperative imaging. As a fluorophore we have used indocyanine green (ICG). ICG has been used for many decades to assess cardiac function, cerebral perfusion and liver perfusion.8 It is an inert drug with a safe pharmaco-biological profile. When excited at around 750 nm, it emits light in the near-infrared spectrum around 800 nm. A custom-made multispectral fluorescence imaging camera system was used.9. The aim of this video article is to demonstrate the detection of the SLN using intraoperative fluorescence imaging in patients with cervical and vulvar cancer. Fluorescence imaging is used in conjunction with the standard procedure, consisting of radiocolloid and a blue dye. In the future, intraoperative fluorescence imaging might replace the current method and is also easily transferable to other indications like breast cancer and melanoma.

9 May 2022 in Cardiovascular Research
Verified
Journal Article
Open access
NHNiels Harlaar
Niels Harlaar
DPDaniël A Pijnappels
Daniël A Pijnappels
AVAntoine de Vries
Antoine de Vries